ReviewMedical review (2021)2022
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives.
Review in Medical review (2021), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses inScience advances · 2026Article
- Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
- Echocardiography in cardio-oncology: optimising service delivery.Echo research and practice · 2026Review
- The Evolution of Spatial Omics Technologies Introduces A Novel Avenue for Lung Cancer Research.Genomics, proteomics & bioinformatics · 2026Review
- Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.Biomedicines · 2025Review
- Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment.Nanomedicine (London, England) · 2025Review
- Synthesis, Anticancer Screening, and In Silico Evaluations of Thieno[2,3-Pharmaceuticals (Basel, Switzerland) · 2025Article
- Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors.Cancer letters · 2025Article
- Recent Advancements in Cell-Based Therapies in Melanoma.International journal of molecular sciences · 2024Review
- Trends of older gastric cancer incidence, mortality, and survival in the highest gastric cancer risk area in China: 2010-2019 and prediction to 2024.BMC public health · 2024Article
- Therapeutic applications of RNA nanostructures.RSC advances · 2024Review
- PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.Frontiers in immunology · 2024Review
- Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies.ImmunoHorizons · 2023Article
- A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.Frontiers in pharmacology · 2023Review
- Precision medicine revolutionizes cancer diagnosis and treatment.Medical review (2021) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies, as one of the most important components of host adaptive immune system, play an important role in defense of infectious disease, immune surveillance, and autoimmune disease. Due to the development of recombinant antibody technology, antibody therapeutics become the largest and rapidly expanding drug to provide major health benefits to patients, especially for the treatment of cancer patients. Many antibody-based therapeutic strategies have been developed including monoclonal antibodies, antibody-drug conjugates, bispecific and trispecific antibodies and pro-antibodies with promising results from both clinical and pre-clinical trials. However, the response rate and side-effect still vary between patients with undefined mechanisms. Here, we summarized the current and future perspectives of antibody-based cancer immunotherapeutic strategies for designing next-generation drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.